KRAS-mutant advanced NSCLC: efficacy and clinical outcomes from network meta-analysis and real-world evidence
{{output}}
Background: KRAS is a common driver gene in non-small cell lung cancer (NSCLC). Owing to the absence of universally effective targeted agents and marked heterogeneity, optimal treatment selection for KRAS-mutant NSCLC remains unc... ...
